Kyowa Kirin and Orchard Therapeutics Announce OTL-200 Granted Orphan Regenerative Medicine Product Designation for Early-onset MLD in Japan
(TSE:4151.T), TOKYO, LONDON and BOSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) — Kyowa Kirin Co., Ltd., (TSE: 4151, President and COO: Abdul Mullick, “Kyowa Kirin”) and Orchard Therapeutics announced that Japan's Ministry of Health, Labor and Welfare (MHLW) has granted Orphan Regenerative Medicine Product Designation to OTL-200, also known as atidarsagene autotemcel, an investigational ex vivo […]